According to the findings of a controlled 10-year follow-up research, fracture rate reduced from 100 to 35% in all osteoporosis-affected people who had been treated with Teriparatide for a mean period of 18 months followed by other bone-specific treatment during a 10-year follow-up. Investigators compared people with osteoporosis to placebo-treated osteoporosis people and the general population to assess the long-term impact of subcutaneous Teriparatide on fractures and health-related quality of life.

A total of 40 women (mean age 69 years) suffering from osteoporosis and spinal compression received Teriparatide 20 μg every day for a mean of eighteen months. From a placebo-controlled, randomized, double-blind, growth hormone trial, placebo-treated women with osteoporosis (n = 25, mean age = 60 years) with daily subcutaneous injections for eighteen months were employed as the control group. Dual-energy x-ray absorptiometry was used together with questionnaires at the beginning, 18 months, 36 months, and 10 years thereafter.

Overall, 233 women of a comparable age who were chosen at random from the population served as controls and were followed concurrently. Every fracture was confirmed through an X-ray. Reduction in fractures was reported from 100 to 35% in the teriparatide users to similar levels as in the population sample, 25 to 28% at baseline and following ten years, respectively.

Teriparatide caused a rise in bone mineral density, which, after 10 years, recovered to its pre-treatment values. The Teriparatide group had a poorer health-related quality of life than the general population before, and after therapy, as well as at 10 years. In osteoporosis-affected people, health associated quality of life was low and not affected by bone-specific therapy.

Teriparatide was well-tolerated and efficient with improvement in bone mass in lumbar spine and femoral neck. In severely affected people, it did not enhance health-related quality of life. Teriparatide is suggested as the first-line therapy in secondary prophylaxis of osteoporosis.